{"prompt": "['Clinical Study Protocol', 'A Randomized, Double-blind, Placebo-controlled Study of TEV-50717', '(Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and', 'Adolescents', 'Study Number TV50717-CNS-30046', 'NCT03452943', 'Protocol Approval Date: 25 March 2019']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Clinical Study Protocol with Amendment 05', 'Study Number TV50717-CNS-30046', 'A Randomized, Double-blind, Placebo-controlled Study of TEV-50717 (Deutetrabenazine)', 'for the Treatment of Tourette Syndrome in Children and Adolescents', 'Phase 2/3', 'IND number: 127692; NDA number: NA; EudraCT number: 2016-000622-19', 'Original Protocol Approval Date: 26 February 2016', 'Protocol Amendment 05 Approval Date: 25 March 2019', 'Sponsor', 'Teva Branded Pharmaceutical', 'Products R&D, Inc.', '41 Moores Road', 'Frazer, Pennsylvania 19355', 'United States of America', \"Teva's Development Partner\", 'Nuvelution TS Pharma, Inc.', '101 Main Street, 12th Floor', 'Cambridge, Massachusetts 02142', 'United States of America', 'Confidentiality Statement', 'This clinical study will be conducted in accordance with current Good Clinical Practice (GCP) as directed', 'by the provisions of the International Council for Harmonisation (ICH); United States (US) Code of', 'Federal Regulations (CFR), and European Union (EU) Directives and Regulations (as applicable in the', \"region of the study); national country legislation; and the sponsor's Standard Operating Procedures\", '(SOPs).', 'This document contains confidential and proprietary information (including confidential commercial', 'information pursuant to 21CFR\u00a720.61) and is a confidential communication of Teva Branded', 'Pharmaceutical Products R&D and/or its affiliates and Nuvelution TS Pharma, INC. The recipient agrees', 'that no information contained herein may be published or disclosed without written approval from the', 'sponsor.', '\u00a9 2019 Teva Branded Pharmaceutical Products R&D, Inc. and Nuvelution TS Pharma, INC. All rights', 'reserved.', '1']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'AMENDMENT HISTORY', 'The protocol for Study TV50717-CNS-30046 (original protocol dated 26 February 2016) has', 'been amended and reissued as follows:', 'Amendment 05', '25 March 2019', '86 patients randomized/enrolled to date', 'Amendment 04', '13 September 2018', '35 patients randomized/enrolled to date', 'Amendment 03', '06 November 2017', 'No patients randomized/enrolled to date', 'Amendment 02', '03 October 2017', 'No patients randomized/enrolled to date', 'Amendment 01', '22 June 2017', 'No patients randomized/enrolled to date', 'The Summary of Changes to the Protocol includes the corresponding reason/justification for', 'each change and is provided in Section 17.', '2']\n\n###\n\n", "completion": "END"}